DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Aktueller Standort:
>
> This Story


Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment

 

Oncology Homepage

Carestream Health now shipping MyVue Center Self-Service Kiosk Provides patients with access to imaging exam records quicker

MEVION S250i Proton Therapy System scores CE mark First European installation to be in Netherlands

Researchers develop CT system for imaging extremely small objects Generates high-resolution 3-D images

RaySearch enters boron neutron capture therapy field Will add BNCT as a radiotherapy modality through alliance with Neutron Therapeutics

Can theranostics be the key to completely curing colorectal cancer? Preclinical trials yield promising results

Varian to install ProBeam at Penn Medicine and new hospital in China The 'latest proof of growing worldwide interest' in proton therapy

At PTCOG, research points to a need for greater access to proton therapy Pediatric patients face delays in insurance coverage

Karen Horton John Hopkins names director of department of radiology and radiological science

Proton therapy trumps IMRT for prostate cancer: study Research points to higher survival rates and fewer complications

Clinical trial combining focused ultrasound and immunotherapy underway Aim is to enhance the ability of the immune system to recognize tumors

iCAD's Xoft Axxent balloon applicators

China approves iCAD Xoft Axxent balloon applicators for early-stage breast cancer treatment

by John Fischer , Staff Reporter
The China Food & Drug Administration (CFDA) has approved the use of iCAD’s Xoft Axxent balloon applicators for treating early-stage breast cancer.

Doctors and clinicians in China can now use the applicators, a component of the the Xoft Axxent Electronic Brachytherapy (eBx) System, to administer intraoperative radiation therapy (IORT) to the site of tumors during the lumpectomy for patients with stage one or two breast cancer as well as those with Ductal carcinoma in situ (DCIS) that has not yet progressed to the lymph nodes.

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



“More and more women are searching for effective alternatives for the treatment of early stage breast cancer,” Daniel Arnoff, vice president of global sales at iCAD, told HCB News. “Many women cannot comply with the six to eight weeks of external beam radiation following their surgery. IORT is done at the time of surgery, allowing appropriately selected patients to complete their full course of radiation in one day.”

The Xoft System’s miniaturized x-ray source is inserted into an applicator as a channel for administering a single and exact, high-dose rate of low energy radiation treatment to the lumpectomy cavity. The applicator delivers the dose, targeting the cancer cells directly, so as to reduce exposure of healthy surrounding tissue to the radiation.

The applicators come in different sizes and shapes and can be filled with different volumes of saline to fit the contour of the cavity exactly and enable delivery of a more conformal dose of radiation. They also come in a sterile pack, eliminating the need for sterilization and decreasing the risk of cross-contamination.

Arnoff says the Xoft system and its applicators have the potential to become a standard option for treating breast cancer in China, and that with more research, could be used to treat other forms of cancer.

“As additional data emerge in support of other clinical applications, we expect that other countries, including China, will consider utilizing the Xoft System and its variety of applicators for a range of cancers,” he said.

The Xoft system and its applicators are FDA-approved and CE-marked to treat cancer in any part of the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

Oncology Homepage


You Must Be Logged In To Post A Comment

Werben
Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Übersicht
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Gesundheitsdienstleister
Alle Gesundheitsdienstleister-Tools anzeigen
Jobs/Training
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED